Climb Bio, Inc.
CLYM
$6.97
-$0.16-2.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 28.78% | 5.95% | 11.86% | 197.34% | 123.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 155.47% | 26.93% | 126.54% | 665.99% | 147.23% |
| Operating Income | -155.47% | -26.93% | -126.54% | -665.99% | -147.23% |
| Income Before Tax | -108.13% | -44.89% | 84.21% | -1,124.57% | -131.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -108.13% | -44.89% | 84.21% | -1,124.57% | -131.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.13% | -44.89% | 84.21% | -1,124.57% | -131.15% |
| EBIT | -155.47% | -26.93% | -126.54% | -665.99% | -147.23% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -100.00% | -42.80% | 92.91% | -401.63% | 1.66% |
| Normalized Basic EPS | -232.99% | -42.77% | -20.45% | -399.25% | 44.92% |
| EPS Diluted | -100.00% | -42.80% | 92.91% | -401.63% | 1.66% |
| Normalized Diluted EPS | -232.99% | -42.77% | -20.45% | -399.25% | 44.92% |
| Average Basic Shares Outstanding | 4.06% | 1.48% | 122.69% | 144.09% | 135.09% |
| Average Diluted Shares Outstanding | 4.06% | 1.48% | 122.69% | 144.09% | 135.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |